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Abstract
Epicardial Wireless Pacemaker for Improved Left Ventricular Resynchronization
(Conceptual Design)
Rodney Hawkins
The human body is a well tuned mechanism where systems work in
synergy to provide a healthy quality of life. The human circulatory system
transports oxygenated blood from the heart to the rest of the body delivering the
proper nutrients for cells to function. When the heart malfunctions, serious
complications can arise leading to sudden cardiac arrest. Congestive heart
failure (CHF) is one heart disease that affects the synchrony of the heart’s
ventricles.
Cardiac resynchronization therapy (CRT) has been widely accepted as a
treatment for CHF. Similar to traditional dual chamber pacing techniques, CRT
adds a pacing lead to stimulate the left ventricle. Left ventricular leads are
implanted via the coronary sinus which provides the easiest surgical access to
the left ventricle. Another option for LV pacing is by using an epicardial lead.
This option has proven to be safe and effective but requires major surgery. An
epicardial lead is usually implanted by performing a thoracotomy. Many studies
have been done to show the benefits of bi-ventricular pacing, therefore
developing new methods to gain LV access safely and reliable are highly
desirable.
The epicardial satellite pacemaker, or EPI pacemaker, is a component of
a larger CRT system. This implantable cardiac system is composed of a master
pacing unit with leads and a remote satellite pacing unit. The master unit is a
iv

traditional CRT device electrically coupled to the right side of the heart. It
controls the right atrium and ventricle via transvenous leads anchored to the
endocardium of the heart. The master device generates the pacing pulses to
stimulate the right atrium and right ventricle and a communications module to
transmit pacing commands to the epicardial satellite device. The epicardial
satellite pacemaker is a leadless device mounted directly on the epicardium of
the left ventricle. The epicardial pacemaker can be implanted using a
thoracoscopic procedure during implant of the master unit. In special events, it
can be implanted using prophylactic techniques during heart bypass surgery of
other surgical procedures where access to the heart is available. Much work
needs to be done to prove the technology. But current RF communication
capabilities in today’s devices offer the groundbreaking path to develop a satellite
LV pacing design.
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Chapter 1: Introduction
Congestive heart failure (CHF) is a disease that affects millions of people
worldwide. Every day more cases are diagnosed and if left untreated it can have
deadly results. Congestive heart failure is a disease affecting the ventricular
synchrony of the heart. In its advanced condition, the left ventricle may not pump
enough blood out the heart producing a backfill in the lungs. The lack of
oxygenated blood to the body may also affect physiological function of the body
diminishing the quality of life.
An accepted treatment for CHF has been cardiac resynchronization
therapy (CRT). This therapy was developed in the 1990’s and first commercially
available with an implantable device in 2001. CRT expands traditional pacing
therapy of the right ventricle by including pacing stimulation to the left ventricle.
This requires the addition of another transvenous lead to reach the left ventricle.
The left ventricle chamber is not easily accessible, thus the coronary system
provides the best approach for stimulation. The coronary sinus is the avenue
chosen by most physicians to gain access to the left side of the heart. But
anatomical differences within patients sometimes make it difficult for the
implanting physician to reach the right site for optimal pacing results. Other
challenges encountered include lead dislodgement and/or higher pacing capture
thresholds.
A wireless epicardial pacemaker moves away from traditional pacing
therapy techniques and brings forward a concept for left ventricular pacing. By
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taking advantage of today’s radio frequency capabilities within pacemakers and
implantable cardioverter defibrillators, a wireless device communicating with a
master device may be implanted directly to the epicardium of the left ventricle.
This concept can be proved useful in solving LV access and ensuring the
appropriate site and pacing threshold can be achieved for optimal LV function. It
may also provide additional benefits by allowing a plurality of epicardial
pacemakers to be implanted to deliver multisite therapy.
It is important to have the basic understanding of the heart’s conducting
system, as this is the fundamental model to replicate when designing systems to
sense and pace the heart. Research and development teams are constantly
looking at new ways, methods, and locations to pace the heart in order to
achieve optimal hemodynamic functionality. Traditional methods of drugs and
implantable devices have limitations that are constantly being improved with the
introduction of new products. Through an understanding of the heart’s anatomy,
it may be clear that traditional left lead implants to provide left ventricular
stimulation have many challenges that are patient dependent. And that an
alternate method to send an electrical impulse may be worth experimenting. This
thesis describes in detail the concept of a wireless epicardial pacemaker working
as a satellite device receiving commands from a master device. It addresses the
benefits of this new technology as well as the unresolved challenges left for
future work.

2

Chapter 2: The Heart
2.1

The Circulatory System
The circulatory system, along with the endocrine and nervous systems,

make up the principle coordinating and integrating systems of the human body.
Whereas the nervous system primary function is dealing with communication and
the endocrine system with regulation of certain body function, the circulatory
system function is to transport and distribute essential nutrients to the body’s
cells and remove metabolic by-products. It also serves as a control mechanism
to regulate body temperature and adjustment of O2 and nutrients supply in
different physiologic states.
The circulatory (or cardiovascular) system accomplishes these functions
by using a pump, a series of distributing and collecting tubes, and an extensive
array of thin vessels that allow rapid exchange between the tissue and the
vascular channels. The pump mentioned above is the heart. The heart consists
of two pumps in series: the right heart and the left heart. In turn, each of these
hearts is a pulsing two chamber pump composed of an atrium and a ventricle.
The atrium functions primarily as a weaker pump for the ventricle to help blood
into the ventricle. The ventricle then supplies the main force to propel the blood
either to the lungs (right ventricle) or the rest of the body (left ventricle).
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Figure 1 Cross Section of the Human Heart
The right ventricle propels blood from the heart to the lungs for exchange
of O2 and CO2. This function is also known as the pulmonary circulation. The left
ventricle propels oxygenated blood to all other tissues of the body. This function
is known as the systemic circulation. The flow of blood throughout the body is
also unidirectional. This is accomplished by systematically arranged flap valves
that prevent blood from flowing backwards.

2.2

The Heart Anatomy
The human heart has a mass between 250 and 350 grams and is about

the size of a fist.1 It is located in the chest area in front of the vertebral column
and behind the sternum inside the rib cage for protection. It is enclosed in a
doubled-wall sac called the pericardium. The outer part of this sac is called the
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fibrous pericardium. This sac also protects the heart, anchors to its surrounding
structures, and prevents the heart from overfilling with blood. The wall of the
heart is composed of three layers, the epicardium, the myocardium, and the
endocardium. The outer layer is called the epicardium or visceral pericardium
since it is also known as the inner wall of the pericardium.

The middle layer is

the myocardium and it is composed of muscle that contracts. This is the thickest
layer and it is known as the “workhorse” of the heart. The inner layer of the heart
is the endocardium and it is composed of tissue that is in contact with the blood
the heart pumps. It has a smooth surface which allows easy blood flow
throughout the heart chambers. See figures 2 and 3 below.

Figure 2 Heart Muscle Tissue Layers31
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Figure 3 Cross Section of Heart Wall2
The heart has four chambers. The upper chambers are known as the
atria while the lower chambers are known as the ventricles. The right atrium
receives deoxygenated blood from the body via the superior and inferior vena
cava. Blood is passed to the right ventricle through a valve where the blood is
pumped to the lungs to collect oxygen. In a similar fashion, oxygenated blood
from the lungs returns to the left atrium and it is pumped through a valve to the
left ventricle. The left ventricle pumps the oxygen rich blood to the rest of the
body through the aorta.
Blood flow within the four chambers of the heart is also unidirectional, from
the atria to the ventricles and from the ventricles to the arteries. This is
accomplished by four valves within the heart (tricuspid, mitral, aortic, and
pulmonary.1
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Figure 4 Heart Chambers and Valves2
The tricuspid valve separates the right atrium from the right ventricle whereas the
mitral valve separates the left atrium from the left ventricle. These two valves are
also known as atrioventricular valves. The pulmonary valve separates the right
atrium from the pulmonary artery. The aortic valve separates the left ventricle
from the aorta. These two valves are also known as semilunar valves.
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Chapter 3: Electrophysiology of the Heart
The nervous system controls various aspects of the cardiac function
including the rate at which the heart beats and the strength of the contractions.
However, cardiac function does not require a fully functional nervous system.
The heart possesses properties of automaticity (the ability to initiate its own beat)
and rhythmicity (the ability to regulate its pacemaking activity.) 3 Cells located in
all four chambers of the heart are capable of initiating beats, although such cells
reside primarily in the nodal tissues of the heart. The region that ordinarily
generates the greatest frequency of beats is the sinoatrial (SA) node. This node
is known as the “natural pacemaker” of the heart. The electrical signals from the
SA node travel through the atria to the atrioventricular node or AV node. The
conductive system is organized in such a way that the cardiac impulse does not
travel too fast from the atria to the ventricles. The AV node provides an electrical
delay to allow the atria to empty the blood into the ventricles before ventricular
contraction is initiated.
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Figure 5 Cardiac Conduction System4
After the delay, the AV node sends an electrical signal through the “bundle of his”
to the bundle braches and then to the Purkinje fibers. The action potential is then
propagated to the endocardium at the apex of the heart and then to the
ventricular myocardium which in turn contracts the ventricles.5 But other parts of
the heart can exhibit rhythmic excitation in the same way the SA node fibers do.
This is primarily true for the AV node and the purkinje fibers. The AV node fibers
when not stimulated from an outside source can discharge at an intrinsic rhythm
of 40 to 60 beats per minute. In a similar way, the Purkinje fibers can discharge
at a rate between 15 to 40 beats per minute. 6 These rates are much lower than
the intrinsic rhythm of the SA node at 70 to 80 beats per minute.6 This difference
in frequency is why the SA node controls the heart rhythm and it is called the
natural pacemaker of the heart. Before the AV node or the Purkinje fibers can
reach their own threshold for self excitation, the SA node emits a new impulse
discharging both the AV node and the Purkinje fibers. If the SA node would ever
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fail, the AV node or Purkinje fibers at their low frequency output would not
provide the necessary cardiac output required by the human body.
Occasionally, other parts of the heart develop a rhythmical discharge rate
that is much faster than the SA node. Often enough this occurs on the AV node
or the Purkinje fibers when these become abnormal. In this instance, the natural
pacemaker of the heart shifts from the SA node to the AV node or Purkinje fibers.
Under rare conditions, a random point in the atria or ventricle develops excessive
excitability and becomes the pacemaker, known as ectopic foci. A pacemaker
elsewhere than the SA node is called an “ectopic pacemaker”.6 An ectopic
pacemaker causes an abnormal sequence of contractions of different parts of the
heart and can lead to significant debilitating pump functionality. If left untreated,
it can develop more serious conditions like congestive heart failure.
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Chapter 4: The Coronary System
Perhaps the most common cause of congestive heart failure is coronary
artery disease. This disease is the narrowing of the small blood vessels that
supply oxygenated blood to the heart. A brief understanding of the coronary
system and its physiology will give us a better understanding of the challenges
today’s engineers face in developing new treatments for CHF.
While the circulatory system is busy providing oxygen and nourishment to
all the cells in the body, the heart is working its hardest pumping the blood. And
to work properly, the heart also needs blood and nourishment. After all, the heart
is another organ in the body. The coronary system is the blood vessels within
the heart that circulate blood to the heart and from the heart. This system of
blood vessels includes arteries and veins. Arteries are blood vessels that carry
oxygenated blood from the heart to the heart cells. Veins are blood vessels that
bring back deoxygenated blood to the heart. The coronary circulation refers to
the movement of blood through the heart tissue. The circulation of blood through
the heart is just one part of the overall circulatory system of the body.7

4.1

Coronary Circulation (How it Works)
The heart muscle requires oxygen rich blood like any other organ in the

body to function properly. Blood is supplied to the heart by its own vascular
system called the coronary circulation. The aorta, the largest artery in the body,
branches off into two main coronary blood vessels, the right coronary artery and
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the left coronary artery. These two arteries branch into smaller arteries and
finally into capillaries which supply the oxygen rich blood to the heart tissue. In a
similar manner, the coronary veins bring back the oxygen free blood from the
heart tissue back to the right side of the heart to be pumped into the lungs.
The right coronary artery or RCS supplies blood to the right side of the
heart. The RCA lies in the right atrioventricular (AV) groove between the right
atrium and right ventricle. The left coronary artery or LCA itself branches into two
separate arteries, the left anterior descending artery (LAD) and the circumflex
artery.

Figure 6 Coronary Arteries of the Heart30
These two arteries supply the left side of the heart with oxygen rich blood. The
LAD travels in the interventricular groove and continues all the way down to the
apex of the heart. The LAD supplies most of the blood required by the left
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ventricle. The circumflex lies in the AV groove between the left atria and left
ventricle.
The coronary sinus vein returns most of the coronary venous blood from
the left ventricle to the right atrium. The coronary sinus returns approximately
75% of the total coronary blood flow to the heart. 6 The coronary sinus is located
in the right atrium and runs transversely in the groove between the left atrium and
left ventricle. It also prolongs down the posterior apex of the left ventricle. Most
of the coronary blood flow from the right ventricle returns to the heart through the
anterior cardiac veins that flow directly into the right atrium.

Figure 7 Coronary Veins of the Heart8
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4.2

Coronary Artery Problems

Coronary artery anomalies are rare. Early detection and evaluation is
essential because of its association with sudden cardiac death. Today’s
technology advancements with computer imaging have made it possible to detect
coronary anomalies through the use of CT scans. Coronary anomalies can be
classified into anomalies of origin, the course, and termination. These
anomalies can be further classified as:
1. Anomalies of the Origin9
•

Origin of coronary artery from pulmonary artery

•

Single coronary artery

2. Anomalies of the Course9
•

Myocardial bridging

•

Duplication

3. Anomalies of Termination9
•

Coronary artery fistula

•

Extra-cardiac termination

Interarterial left coronary artery is the most common and clinically
significant anomaly. This is an anomalous origin of the left coronary artery
coursing between the aorta and the pulmonary artery. Patients with this anomaly
frequently suffer sudden cardiac death.
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Figure 8 Interarterial Left Coronary Anomaly9
Another origin anomaly is known as “ALCAPA”. In this anomaly, the left
coronary artery begins only from the pulmonary artery. As a result, the left side of
the heart is supplied with relatively low oxygenated blood under low pressure.
This anomaly more than frequently leads to sudden cardiac death. ALCAPA is a
rare congenital anomaly accounting approximately 0.25% – 0.50% of all
congenital heart diseases.9 Approximately 85% of patients’ present clinical
symptoms of congestive heart failure or CHF within the first 1-2 months of life.9

Figure 9 ALCAPA Coronary Anomaly9
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An anomaly of the course is myocardial bridging. This anomaly occurs
when a section of the artery buries itself under the myocardium. A normal
healthy artery typically rest on top of the myocardium. This is commonly
observed in the left anterior descending (LAD) coronary artery. If this happens,
the depth of the artery under the myocardium is more important than the length
of the myocardium bridging. Clinicians are still debating whether myocardium
bridging has any hemodynamic significance.

Figure 10 Myocardial Bridging Coronary Anomaly9
An anomaly of termination is called fistula. This anomaly occurs when the
LAD gives rise to a large septal branch that terminates in the right ventricle (see
blue arrow in picture below). In this case, the LAD bypasses the myocardial
capillaries and terminates directly inside the heart chamber. Major sites of fistula
are the right coronary artery (40-60%), the LAD (30-60%), the circumflex, or a
combination of both.10 About 90% fistulas terminate on the right side of the heart
and in rare occasions on the left side or the pericardium. Of the right side
termination anomalies, the most frequent occur in the right ventricle followed by
16

the right atrium. Small fistulas are typically benign and can only be detected in
routine echocardiograms or autopsies. On the other hand, larger fistula can
progressively enlarge and lead to CHF and myocardium infarctions. It can
potentially be deadly in older patients.

Figure 11 Fistula Coronary Anomaly9
The human body is a precisely engineered machine that works in synergy
with multiples systems. When one system fails, health issues may develop that
could lead to death. Any of the above mentioned coronary ailments can lead to
congestive heart failure or sudden death. Cholesterol buildup in the coronary
arteries may prevent sufficient blood from reaching the heart tissue. Often
enough, this condition leads to chest pain. If the blood supply is completely
obstructed, a heart attack may occur. The coronary disease may contribute to
high blood pressure which in time can lead to CHF. Heart valve problems can
also lead to CHF. When the valves do not work properly, the heart muscle has to
work harder to keep the blood flowing.
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Chapter 5: Congestive Heart Failure
5.1

Definition of Congestive Heart Failure
What is congestive heart failure? Congestive heart failure or CHF is a

condition in which the heart can no longer pump enough blood to the rest of the
body. It is a heart disease that can affect the right ventricle, the left ventricle, or
both. It is most commonly a chronic condition that develops overtime, but it can
also happen suddenly in rare cases. When CHF affects the right heart side, the
right ventricle loses its ability to pump blood to the lungs. A common symptom of
right side failure is the swelling of the feet and lower legs. As the condition
worsens, the upper legs swell and eventually the swelling moves to the abdomen
area. When heart failure affects the left side, the left ventricle decreases its
ability to pump blood to the body. The left ventricle receives highly oxygenated
blood from the lungs ready to be distributed throughout the body. A common
symptom of left side heart failure is breathing difficulty. As the left ventricle fails
to empty its chamber, fluid starts collecting in the lungs which may lead to
“pulmonary edema” if left untreated. The extra fluid in the lungs or “congestion”
prevents the airways to expand normally as a person inhales. This creates the
shortness of breath especially when the person is being active.
Heart failure is classified by two stages. It can either be systolic or
diastolic heart failure. Systolic heart failure is diagnosed when your heart can no
longer pump or eject enough blood out of the heart efficiently. Diastolic heart
failure is diagnosed when your heart ventricles do not fill up with enough blood to
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pump out. In most cases, the heart can contract normally but it has become stiff
and less compliant. In either case, the danger is that your heart cannot pump
enough blood to the rest of the body, especially when the person is active. As
the pumping ability of the heart is diminished, blood may start to back up in
different areas of the body producing congestion of the lungs, the liver, and the
body’s extremities like arm and legs. As a result, there is a lack of oxygen being
supplied to these organs or body cells which reduces their ability to function
properly. The long term prognosis can be deadly as organ failure may be the
result of an untreated condition.
A common clinical measurement for the heart’s ability to pump blood
effectively is called the “ejection fraction” or “EF”. The ejection fraction is a
calculation of how much blood is ejected from the left ventricle, also known as
“stroke volume”, divided by the maximum volume remaining in the left ventricle at
the end of the relaxation phase or “diastole”. A normal ejection fraction is greater
than 50%.6,11 Systolic heart failure is diagnosed when the EF is less than 50%.
In diastolic heart failure, the ejection fraction is typically normal. Diastolic heart
failure is more common in patients older than 75 years, especially in women who
suffer from high blood pressure.
Heart failure affects 1% of people aged 50 years, about 5% of those aged
75 years or older, and 25% of those aged 85 years or older.11 As the expectancy
living age increases, the number of elders will also increase. This number is
continually increasing therefore the number of people diagnosed with heart
failure will also rise. In the United States nearly 5 million people live with heart
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failure. And every year about 550,000 new cases are diagnosed.11 The rate of
death from heart failure is about 10% after the first year being diagnosed. About
50% of people with CHF will die within 5 years after being diagnosed.11 This
statistics do vary by patient’s exact diagnosis and therapy, nonetheless it is
classified as a high death risk disease. Many advances have been made in
research and development for new therapies, both in drug or medical device
treatments. This is a welcome sign of relief for patients who have to live with this
life debilitating condition.

5.2

What Causes Congestive Heart Failure?
Congestive heart failure is not a disease but rather a syndrome that can be

developed by several factors. CHF is a weakening of the heart caused by the
following or a combination of several:
•

Weakened heart muscle: the heart muscle can become weak because
of damage and thus loose its capability to contract as it should. This
damage to the muscle more often enough occurs from coronary artery
problems.

•

Damaged heart valves: valves in the heart allow blood to flow in one
direction only. When these fail, blood may flow back or not enough
through the valve. An incompetent valve is a valve that does not close
properly and allows blood to flow backwards in the heart. The heart then
needs to work extra hard to keep the same blood output to the rest of the
body. A stenotic valve is a valve that does not open properly restricting
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the blood flow through the narrow opening. The heart has to work harder
to ensure enough blood passes between the chambers and to the rest of
the body.
•

Blocked coronary vessels: the coronary arteries provide the blood to
the heart for it to work properly. If the heart does not get its normal supply
of oxygenated blood, it may in turn start to fail.

•

Toxic exposure: excessive intake of drugs

•

Infections

•

High blood pressure: increase blood pressure in the circulatory system
can lead to an increased heart size or thickened left ventricular wall. This
condition reduces the compliance of the ventricle wall and the ventricle’s
ability to contract.

•

Prolonged arrhythmias: slow weakening of the heart

Congestive heart failure can also developed by lifestyle choices. Unhealthy
habits such as smoking or excess use of alcohol can lead to heart failure. An
unhealthy diet and a lack of exercise that leads to obesity can contribute to heart
failure. Not because of increased weight but rather the accompanying factors of
obesity such as increased blood pressure and diabetes.

5.3

How to Treat CHF?
The treatment of CHF depends on the exact cause and it can usually be

treated effectively. The overall goals of the treatment are to correct the
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underlying causes, relieve the symptoms, and prevent further damage to the
heart. In order to determine the best treatment option, physicians usually
classify the type of CHF according to the New York Heart Association (NYHA)
classification system.

Table 1 The Stages of Heart Failure - NYHA Classification13
Class

Patient Symptoms

Class I (Mild)

No limitation of physical activity.
Ordinary physical activity does not
cause undue fatigue, palpitation, or
dyspnea (shortness of breath).

Class II (Mild)

Slight limitation of physical activity.
Comfortable at rest, but ordinary
physical activity results in fatigue,
palpitation, or dyspnea.

Class III (Moderate)

Marked limitation of physical activity.
Comfortable at rest, but less than
ordinary activity causes fatigue,
palpitation, or dyspnea.

Class IV (Severe)

Unable to carry out any physical
activity without discomfort. Symptoms
of cardiac insufficiency at rest. If any
physical activity is undertaken,
discomfort is increased.

22

Chapter 6: Cardiac Resynchronization Therapy
6.1

Definition of CRT
One way to treat heart failure is to place a device in the chest to assist

with the electrical activity of the heart. People who suffer from heart failure
normally develop a problem with their heart’s electrical function. Whereas
traditional devices only applied therapy to treat electrical anomalies of the right
side of the heart, a new type of therapy called cardiac resynchronization (CRT) is
available for heart failure patients. CRT involves the use of electrical signal to
stimulate and pace both the right and left ventricles. Roughly three to four out of
every ten people with heart failure have an electrical problem in the conduction of
electrical impulses to the lower chambers of the heart.12
Cardiac resynchronization therapy is a fairly new type of treatment. The
first implantable device supporting CRT therapy was introduced by Medtronic in
2001. It was a CRT pacemaker or CRT-P called InSync®. Since then, the
technology has evolved to include ICDs that can also deliver CRT therapy.
The concept behind cardiac resynchronization therapy is very simple. It attempts
to restore the normal coordinated pumping action of the right and left ventricles of
the heart by correcting the electrical problems associated with CHF. Typically,
electrical problems arise from conduction blocks on the bundle branches which
create contraction delays between the ventricles. The result is an asynchronous
contraction of the ventricles which reduces the pumping ability of the heart. By
restoring the synchrony of the heart chambers, CRT is perhaps controlling future
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progression of CHF that can lead to more severe problems. Ultimately, CRT is
bringing an improved quality of life by treating the symptoms associated with
CHF.
There are two types of CRT devices available. The first one delivers only
electrical signals and is called a CRT pacemaker. The other combines a
pacemaker with a defibrillator for those patients who are at high risk of sudden
cardiac death due to a fast heart arrhythmia. A defibrillator is a device commonly
used to shock patients out of a deadly fast rhythm. This device is called a CRT
implantable cardioverter defibrillator or CRT ICD.
The CRT system consist of three parts, the pulse generator which delivers
the electrical signals, the lead which carry the electrical signals from the
generator to the heart, and the lead electrodes which transmit the signals to the
heart.

Figure 12 CRT-D Device and Leads Implanted Inside the Heart
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A non CRT pacemaker usually has two electrical leads going from the
device to the heart, one placed in the right atrium and another placed in the right
ventricle. These two electrical leads will ensure the heart maintains a normal
coordinated pumping relationship between the upper and lower chambers. A
CRT device has an additional electrical lead that connects the device to the left
ventricle. This third lead is routed through the coronary sinus and placed on the
outer surface of the left ventricle. The third lead allows the device to coordinate
the electrical stimulus of the left ventricle and bring both ventricles back into a
synchronous pumping action. This type of therapy is sometimes referred as “biventricular” or “bi-v pacing” because both ventricles are being stimulated.
The development of CRT arose from the studies that showed 40% of CHF
patients had an interventricular electrical conduction problem. This condition
often led to worsening CHF symptoms that terminated in death. A typical
candidate that would benefit from CRT suffers from NYHA class III or class IV
heart failure and their ejection fraction is below 50%.

6.2

CRT Benefits
Many clinical trials have been performed to prove the benefits of cardiac

resynchronization therapy. The results of these trials over the last decade have
shown reduction in hospitalization occurrences and mortality rate on patients who
received CRT.
The MIRICLE clinical trail sponsored by Medtronic evaluated the effects of
CRT on quality of life and symptoms in patients with moderate or severe heart
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failure. The trial examined the safety and efficacy of CRT combined with
traditional ICD therapy. The results found an improved quality of life after six
moths of combined CRT and ICD therapy as evaluated by the “Minnesota Living
with Heart Failure Questionnaire”. The results also showed improved functional
capacity and exercise tolerance in patients with advanced HF. However, the trial
endpoints did not include mortality or hospitalization measurements. The safety
and efficacy of CRT was raised in part due to questions with lead placement and
possible interference from the addition of bi-v pacing and ICD therapy. The trial
showed that CRT does not interfere in the delivery shock therapy but concluded
that left ventricular lead placement is not without its challenges. Transvenous LV
lead implantation was unsuccessful in 12% of the patients in the study.14 It was
also noted that once implanted, LV leads were prone to dislodgement.
The COMPANION study was the largest CRT device trail and the first
designed to study the mortality and hospitalization rates as the primary
endpoints. It was originally forecasted that up to 2200 patients would be
required, although that study was conducted with 1634 patients. All the patients
in the study were under optimal pharmacological therapy (OPT) with the
additional therapy of CRT-P or CRT-D for a selected group. The primary
endpoint of death or any hospitalization showed a reduction of about 19% for
both CRT-P and CRT-D patients as compared to the OPT alone therapy
patients.15 The secondary endpoint of all cause mortality showed a reduction of
24% for CRT-P vs. OPT and a reduction of 43% between CRT-D vs. OPT.15 The
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results of the COMPANION trial gave additional proof regarding the benefits of
CRT .
Additional clinical trials like the MUSTIC trial and the CARE-HF trial have
provided additional data supporting the value of CRT. The MUSTIC results
concluded that CRT improved exercise tolerance and quality of life for patients
with chronic heart failure and interventricular conduction delay. The trial also
concluded a 66% reduction in hospitalization occurrences due to heart failure
complications.16 The CARE-HF trial also focused on mortality and hospitalization
as endpoints for CRT benefit. The trial compared CRT to normal OPT treatment
in 813 patients. The trial showed a reduction of 46% in combined death or heart
failure hospitalization. CRT was also associated with a 37% reduction in the risk
of mortality.17
Cardiac resynchronization therapy can substantially improve the quality of
life for patients suffering from NYHA class III or class IV heart failure. The
physiological benefits of CRT can be seen in the improved tolerance for
exercising. Additionally, CRT has proven to reduce the rate of mortality and
decrease the occurrence of hospitalization.

6.3

CRT and LV Pacing Complications
The benefits of CRT to treat congestive heart failure are numerous,

however there is much work to be done to increase the efficacy and optimization
of this therapy. Several challenges associated with individual’s anatomies make
the delivery of CRT more troublesome. Differences in patient’s coronary system
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anatomy make it difficult for physicians to implant an LV lead through the
coronary sinus. In such cases, these patients are eliminated from candidacy for
traditional CRT. In other instances, although the majority of the population has a
normal working coronary system, small anatomical differences in the coronary
vein produce a challenge to the implanting physician to locate the LV lead
appropriately. These challenges are associated with differences in the vein
diameters and vessel turns. The implant procedure for an LV lead is more
challenging because physicians must locate a region where good capture
thresholds can be achieved and the site of most delay for left ventricular
mechanical activation.18 Without a well positioned LV lead, CRT devices lose
their ability to perform cardiac resynchronization. Other complications with LV
implant include lead dislodgement, coronary sinus thrombosis, loss of pacing
capture, and stimulation of the diaphragm.
Other treatment methods are constantly being developed and tested to
provide alternative pacing options to the left ventricle. In an effort to maximize
hemodynamic benefit of CRT, the use of an epicardial LV lead may be an option.
An epicardial lead is surgically attached directly to the epicardium of the heart.
This procedure requires a thoracotomy and general anesthesia as compared to
local anesthesia for traditional CS LV leads. Once access to the heart is
obtained, the physician maps the best LV site for optimal pacing thresholds. The
lead is actively affixed with sutures to the epicardium and tunneled sub-muscular
to the device pocket. Epicardial leads have shown excellent long term pacing
results with less lead complications when compared to CS LV leads. Although
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epicardial leads are associated with major surgery, it has been shown to be safe
and extremely reliable. Coronary sinus LV lead implantation may be the primary
option for most patients, but for a substantial subset of patients an epicardial lead
may provide the benefits necessary for successful CRT.
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Chapter 7: Epicardial Pacemaker
7.1

Overview of Traditional CRT Therapy
Cardiac resynchronization therapy attempts to restore the synchronous

pacing of both ventricles. First a pacemaker, along with right and left side leads
must be implanted. A CRT system consists of a pulse generator and three
pacing leads. The generator contains a battery and microelectronic computer
that serves as the “devices” brain. The leads are insulated wire coils that carry
electrical impulses produced by the pulse generator to the heart and carry
information from the heart back to the pulse generator. In a CRT system, one
lead goes to the right atrium, the second lead to the right ventricle, and the third
lead to the left ventricle. Right heart leads are implanted intravenously via the
superior vena cava and anchored to the endocardium of the heart. CRT left side
leads are most commonly implanted via the coronary sinus to the post lateral
side wall of the left ventricle. Many clinical trials have shown the benefits of CRT
for patients suffering from NYHA class III or class IV heart failure. These CRT
candidates can benefit from ventricle resynchronization by ways of an improved
quality of life and less hospitalization events arising from HF complications.
Although it is generally true that CRT patients tend to be older, CRT
device implants can also be performed in young adults. It is possible to have an
electrical defect in the heart without having any other heart problem. The natural
pacemaker may fail for unknown reasons establishing an ectopic site for the new
pacemaker. With today’s advancement in technology, if no other physical
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limitation is present, it is possible for anyone with a CRT device to live a normal
active life.
Several methods of implanting a CRT system are available. The choices
depend primarily upon health, age, and patient’s anatomy. The most common
involves implanting the insulated leads into the heart through the veins of a
patient who is under mild anesthesia. The pulse generator is implanted under
the skin in a specially prepared pocket in the right or left upper chest. The leads
are connected to the pulse generator and the device secured to the pocket by
sutures. This surgery typically takes about 2 hours and it is often performed in a
cardiac lab. Fifty percent of this time is usually spent locating the appropriate LV
lead site and advancing the lead. Another method involves the use an of
epicardial lead instead of a transvenous LV lead. The implantation procedure for
an epicardial lead requires extensive surgery and is performed with the patient
under complete anesthesia.

7.2

The Epicardial Satellite Pacemaker Concept
The epicardial satellite pacemaker concept was developed to address

major challenges seen today to gain left side pacing access for CHF patients.
The concept is a collection of the benefits seen from coronary sinus implants and
epicardial lead implants.

Biventricular pacing has proven to be an effective

therapy for treating patients with congestive heart failure. Unfortunately when
trying to implant a CRT system, occasionally it may be difficult to gain access to
the left side of the patient’s heart through the coronary sinus (CS). This problem
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could be associated with a small CS diameter which prevents lead advancement.
The trajectory of the CS could be abnormal whereas it prevents establishing an
optimal LV pacing site or the physician may not be able to keep the lead in a
stable position. An epicardial lead surgically attached to the heart addresses the
above concerns. However, this procedure requires major surgery and prolonged
recovery times for the patient. The epicardial satellite pacemaker concept is
intended to resolve the conduction problems, anatomical differences within
patients, and the surgical risks and side effects associated with a thoracotomy.

7.3

How the Epicardial Pacemaker Works
A CRT system is an implantable cardiac system that treats patients with

congestive heart failure (CHF). This particular cardiac system is composed of a
master device, intravenous leads, and a satellite pacing device. The master
device provides the pacing pulses to the right side of the heart via transvenous
leads anchored to the endocardium of the heart. The master device also
contains a communication module that sends pacing commands to the satellite
device. The satellite device is a leadless pacing output device anchored directly
to the left ventricular epicardial wall of the heart. This satellite device mentioned
above is the epicardial pacemaker or EPI pacemaker.
Figure 13 shows a CRT system comprised of the master & epicardial
pacemaker device. The master device (item 102) is shown connected to the
heart through traditional intravenous lead (items 112 & 114). The EPI
pacemaker (106) is shown directly attached to the left ventricle. This cardiac
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system supports multi chamber detection and stimulation therapy, including
biventricular pacing to treat a patient with CHF. The EPI pacemaker can be
implanted onto the left ventricle using thoracoscopic procedures during implant of
the master device. In special events, the EPI pacemaker may be implanted
using prophylactic techniques during bypass heart surgery or in cases where
heart access is available. The EPI pacemaker communicates with the master
device using wireless communication methods like RF. This is represented by
link 110. The EPI pacemaker is not intended to deliver shock therapy, but in
cases where a CRT-D device is used as the master unit, the EPI pacemaker may
contribute to shock therapy by enabling better detection of arrhythmias. By
noting ECM irregularities between the EPI pacemaker and the right ventricle
lead, fibrillation may be able to be detected with confidence.

Figure 13 CRT Cardiac System with Epicardial Satellite Pacemaker19

33

The EPI pacemaker is capable of pacing the left ventricle under direct
command of the master device. Depending on its programmable settings, the
EPI pacemaker may be set to respond to various inputs. It may be programmed
to directly pace according to an output set by the master device or it may be
programmed to sense artifacts from the right ventricle lead and apply a pacing
pulse in response. Yet another programming setting could be a combination of
both, sensing artifacts and direct commands from the master device.

7.4

Description of the Epicardial Pacemaker
In its most simple embodiment and functionality, the EPI pacemaker is a

passive device. It is configured to only pace the left ventricle in response to
commands from the master device. The EPI pacemaker has a housing made out
of commercially pure titanium. The housing protects the microelectronic
components in addition to holding the battery in place. The housing is internally
insulated by polyimide tape to prevent shortening of the battery. In addition to
the battery, the housing contains all the electronic components

Figure 14 Epicardial Satellite Pacemaker

34

The EPI pacemaker also includes a battery to supply operating power to
all the electrical components. The battery is capable of operating at low current
drains for long periods of time. The battery is also capable of providing pulses
with sufficient voltage to stimulate the left ventricle.

Figure 15 Battery for Epicardial Satellite Pacemaker
The microelectronics of the EPI pacemaker is considered the brain of the
device. It is tasked for receiving signals from the master device and in turn
producing a pacing output to stimulate the left ventricle. It consists of a single
layer PCB, a PIC controller and a capacitor.

Figure 16 Electronics for Epicardial Satellite Pacemaker
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An electrode is mounted to the front surface of the device to deliver the
pacing pulses. The electrode has a helical shape to facilitate perforation of the
pericardium and to be screwed into the epicardium. Additionally, it provides an
active fixation anchor to the heart tissue. The electrode is assembled to a
titanium lid by brazing a ceramic ring to isolate the two metals. The helical
electrode is made of 80% platinum and 20% iridium.

Figure 17 Epicardial Satellite Pacemaker (Exploded View)

7.5

Benefits over Traditional CRT Leads
Within the same CRT system, multiple epicardial pacemakers may be

used. A physician may elect to implant multiple EPI pacemakers at different
locations of the heart. This approach gives the physician the ability to determine
which one is the most effective at applying the pacing pulses. In another
instance, the physician may elect to implant multiple EPI pacemakers in physical
proximity to each other. Initially all the EPI pacemakers can be turned off, and
after implantation is complete, activate one at a time. As the battery runs low on
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the active EPI pacemaker, that particular one can be turned off and a new one
activated.
Another benefit of an EPI pacemaker cardiac system is multi-site pacing.
The system can be configured to support triple timing ventricular pacing to obtain
optimal heart hemodynamics. One EPI pacemaker can be positioned one
centimeter down from the ventricular base by the cardiac vein. A second EPI
pacemaker can be positioned 3 centimeters down by the same vein. Then, the
first EPI pacemaker is paced and the second one paced 10 milliseconds later.
Finally, the RV tip electrode is paced 15 milliseconds later. This pacing method
is extendable to four or more EPI pacemakers if desired.
The ability to implant the EPI pacemaker using thoracoscopic procedures
is a great improvement over thoracotomy procedures needed for an epicardial
lead. Because the EPI pacemaker is wireless, there is no need for tunneling the
lead to the device pocket. Therefore the EPI pacemaker can be implanted using
thoracoscopy over thoracotomy. This minimizes trauma to the patient and
reduces recovery periods. In addition, a thoracoscopy can be performed under
minimal sedation and local anesthesia as compared to general anesthesia
needed in a thoracotomy.
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Chapter 8: Future Work
8.1

Vibration Studies on the Heart Tissue
The heart is a muscle that is constantly in motion. A normal heart beats

an average of 60-70 beats per minute. Under stressful conditions from
exercising, the rate can increase to 130-150 beats per minute. An active fixation
of the epicardial pacemaker is essential for continuous therapy to the left
ventricle. The thickness of the epicardium and myocardium is approximately 1.5
centimeters. Therefore, a relatively small helix is desirable to minimize
perforation of the heart muscle and reduce trauma. On the negative side, it
provides less tissue capture to secure the device to the heart wall. Vibration
tests need to be performed with canine or pig hearts to determine the relationship
between excitation frequency and electrode length.
The epicardial pacemaker is intended to be implanted using a
thoracoscopic procedure. This means the physician needs to deliver the device
through the rib cage and affix it to the epicardium. One unknown factor is the
amount of torque required to screw the device to the epicardium. This
measurement can also have substantial impact on the design of the helical
electrode.

8.2

Signal Resistivity Measurements for RF Communication
RF communication is more efficient in a less conductive environment such

as air. Air has very high resistivity thus it makes it easier to communicate at
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higher frequencies. The human body, on the other hand, is very conductive.
The distance between the master device and the epicardial device and the total
resistivity between the two can affect how the two devices communicate.
Scientific studies have estimated resistivity values of the myocardial tissue. One
study determined that with 100Hz stimulation at 2 V, myocardial resistivity was
approximately 295 Ω•cm. Based upon resistivity, we can estimate the predicted
resistance of tissue between the master device and the epicardial pacemaker

(20)

(20)

Assuming a 1.5cm myocardium thickness and a 10 cm ventricular myocardium
width, the area (A) is 15cm2. Assuming an average distance of 20 cm from the
master device pocket to the epicardial pacemaker, the predicted resistance can
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be calculated to be 393.3 Ω. The further the master device is from the epicardial
pacemaker, the larger resistivity between the two. In a similar manner, the
heavier the patient, the more fatty tissue present between both devices. These
values are low in comparison to other RF applications which could limit the
communicating effectiveness. These initial differences could be resolved by
programming capabilities within the master device. But in time, if patient’s
resistivity fluctuates, communicating frequencies may vary which will require
physician intervention. The danger is for pacer dependent patients where the
possibility of losing communication between devices and not delivering therapy
may occur.

8.3

Gel to Promote Adhesion and to Reduce Scar Tissue
One potential problem with the epicardial pacemaker and its screw in

electrode is irritation to the heart tissue that occurs due to the movement of the
electrode as the heart beats. This irritation causes the body to build scar tissue
around the affected area, in this case around the electrode. As scar tissue builds
up, higher voltages are required to pace the heart. This could result in lower
battery life for the epicardial pacemaker and perhaps the need for more frequent
replacements.
To alleviate this problem, a soft gel material can be affixed to the outer
face of the lid surrounding the electrode (figure 18). This gel-like material may be
affixed to the lid by any well known medical adhesives. This material can serve
multiple purposes. The gel can facilitate attachment of the epicardial pacemaker
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to the heart tissue and absorb shocks as the heart beats and moves. The gel
material can also promote tissue growth and allow tissue to grow into the gel to
hold and anchor the device to the heart muscle. The gel material may also
contain a steroid, such as dimethyl sulfoxide (DMSO) to reduce the immune
response of the body and aid in preventing irritation and inflammation to the
implant area.19

Figure 18 Epicardial Pacemaker with Steroid Eluting Gel

8.4

Future Design Considerations (The Pericardium)
Although the benefits of an epicardial pacemaker seem to provide a safe

and viable option to traditional transvenous LV leads, the approach has its
challenges. These include whether the pericardium needs to be surgically
opened and closed after implant. The pericardium serves several mechanical
functions. Besides constraining the heart in the thoracic cavity, it has
hemodynamic influences on the ventricles during diastolic filling. Several studies
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have been done to assess the benefit of closing the pericardium or leaving it
open after thoracotomy.
One study concluded that pericardial closure is unlikely to have any
significant harmful effects in the majority of patients who maintain a good
circulatory state after surgery. For these patients, it is reasonable to close the
pericardium as long as the pericardium does not appear to be taut. However, for
ill patients who started with a low cardiac output, closure of the pericardium had
adverse effects by reducing cardiac output as much as 14%.21 The study
suggested that cardiac function may be impaired by pericardial closure after
cardiac surgery because of some degree of constriction of the heart chambers.
For these patients it was recommended to leave the pericardium open to avoid
any further stress to the blood circulation.
Another study showed the significant effect on diastolic filling of the left
ventricle when the pericardium was closed. However, when the pericardium was
opened, it resulted in an increase cardiac index (cardiac output divided by body
surface area). The increases can be attributed to the Frank-Starling mechanism
to increased left biventricular preload.22 With the pericardium open, the ventricle
is less restricted and allowed to fill with more blood. This in turn has an
improvement in left ventricular systolic performance which should be considered
when contemplating closure of the pericardium.23
There have been several studies describing both the advantages and
disadvantages of pericardial closure after heart surgery. Pericardial closure may
reduce the risk of myocardial injury. This can be more beneficial in future
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surgical interventions such as coronary artery by-pass. However, it should be
considered to be left open for patients who in early postoperative periods show
impaired ventricular function.24

8.5

Future Design Considerations (The Rib Cage)
The rib cage is a bony structure that protects the heart, lungs, and other

underlying organs. It is made of three groups of bones, the sternum, twelve (12)
pairs of ribs, and twelve (12) thoracic vertebrae. Implantation of an epicardial
pacemaker is desired to be accomplished by thoracoscopic procedures. To
accomplish this, the device needs to be small enough to pass through the
intercostal spaces between the ribs.
An intercostal space is wider in the upper ribs. As we move down the rib
cage, the intercostal spaces start to reduce in size. One point to consider in
making an incision through the intercostal space is the neurovascular bundle of
vein-artery-nerve. Therefore it is desired that the intercostal space be penetrated
as low as possible. This reduces the opening for the epicardial pacemaker to
pass through. Typically, epicardial leads are implanted through the fourth
intercostal space.25, 26 It is desired that any thoracoscopic heart surgery to
implant an epicardial pacemaker be performed also through the fourth intercostal
space.
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Figure 19 Intercostal Space in Human Ribs
The initial design and prototyping of the epicardial satellite pacemaker
have conceptually addressed its success. A small device was fabricated capable
of being programmed to deliver a constant 3V pulse. Radio frequency
communication capabilities on current pacemakers and implantable cardioverter
defibrillators make them suitable candidates to function as a master device.
Therefore, the foundation for a wireless epicardial pacemaker is feasible. There
is a lot of work and design refinement that needs to be done before we can move
past conceptual phase and into testing trials. Addressing the future work
concerns will provide a better understanding of the work ahead to physically
prove the benefits of a wireless epicardial pacemaker over traditional CRT.
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Chapter 9: Conclusions
Although people are at a higher risk of developing CHF on the later years
of life, heart failure is a disease that affects everybody without discrimination to
gender or age. Many drugs are available to address the symptoms, but the most
successful therapy has been proven to be cardiac resynchronization. CRT is a
fairly young technology and it is constantly evolving to provide physicians with
the best tools to treat CHF.
The epicardial wireless pacemaker concept takes a step in addressing
today’s challenges with coronary sinus LV implants and epicardial leads. By
directly stimulating the heart tissue, we can obtain lower capturing thresholds.
An epicardial pacemaker can also be positioned on the site for optimal ventricle
stimulation regardless of coronary anatomies. A plurality of epicardial
pacemakers can be implanted to give physicians multisite pacing options.
Finally, the lack of wires eliminates the need to tunnel from the implant site to the
master device pocket. This facilitates a less invasive surgical procedure to
implant the device.
The concept is still in early development stages. Several implant
requirements need to be evaluated, primarily regarding electrode length. The
electrode is the direct connection to the heat tissue to pass the electrical signals
of the device. Electrode length is also critical for determining stability of the
device after implantation. In addition, resistivity measurements need to be
mapped to develop signal algorithms capable of self-regulating changes to
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maintain proper communication between devices. The epicardial pacemaker
concept so far has proven to be feasible, but much work is still needed to be
developed to prove its efficacy to treat CHF.
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